Data from a retrospective study in a cohort of 23 men with breast cancer indicate that eribulin is a safe and effective treatment for men with this disease. All patients had at least a stable disease response, with two complete responses, after a median of six treatment cycles. Patients had a median overall survival duration of 65 months. Four patients had grade ≥3 adverse events, of which two resulted in treatment interruptions, indicating that eribulin is well tolerated.